文献速递血栓与止血

胰高血糖素样肽1受体激动剂与2型糖尿病静脉血栓栓塞:一项目标试验模拟研究

Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation.
PubMed 文献 · Blood Adv · 2025-01-01

本研究采用目标试验模拟方法,基于电子健康记录数据库,将新启用GLP1-RA的2型糖尿病患者与倾向评分匹配的新启用DPP4i患者比较。12个月随访期间,GLP1-RA组静脉血栓栓塞复合终点发生率低于DPP4i组(6.1 vs 7.6事件/1000人年;HR 0.78;95%CI 0.73-0.83),肺栓塞和深静脉血栓结果相似。

要点

  • 与DPP4i相比,GLP1-RA组12个月静脉血栓栓塞复合终点发生率更低(6.1 vs 7.6事件/1000人年;HR 0.78)。
  • 肺栓塞发生率GLP1-RA组2.9 vs DPP4i组3.8事件/1000人年(HR 0.74;95%CI 0.68-0.82)。
  • 深静脉血栓发生率GLP1-RA组3.9 vs DPP4i组4.7事件/1000人年(HR 0.81;95%CI 0.75-0.88)。

核心结论

  • 在这项倾向评分匹配的目标试验模拟研究中,接受GLP1-RA的2型糖尿病患者1年静脉血栓栓塞风险低于接受DPP4i的患者。

研究设计与样本

  • 目标试验模拟(TTE)研究,使用基于人群的电子健康记录数据库。
  • 研究队列共540 258例患者,其中270 129例接受GLP1-RA或DPP4i,新启用GLP1-RA者与倾向评分匹配的新启用DPP4i者进行比较。
  • 主要终点为启用GLP1-RA或DPP4i后12个月内通过ICD-10编码识别的静脉血栓栓塞复合终点。

主要发现

  • 12个月随访期间,GLP1-RA组静脉血栓栓塞复合终点发生率为6.1事件/1000人年,DPP4i组为7.6事件/1000人年(HR 0.78;95%CI 0.73-0.83)。
  • 肺栓塞发生率GLP1-RA组为2.9事件/1000人年,DPP4i组为3.8事件/1000人年(HR 0.74;95%CI 0.68-0.82)。
  • 深静脉血栓发生率GLP1-RA组为3.9事件/1000人年,DPP4i组为4.7事件/1000人年(HR 0.81;95%CI 0.75-0.88)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide 1 receptor agonists (GLP1-RA) are antidiabetic agents recently approved for weight loss. Obesity is an established risk factor for venous thromboembolism (VTE). Moreover, preclinical studies have shown that GLP1-RA may attenuate thromboxane-induced platelet activation. Therefore, we hypothesized that GLP1-RA use may reduce the risk of VTE. We performed a target trial emulation (TTE) using a population-based database of electronic health records to evaluate whether GLP1-RA use is associated with a reduction in VTE in patients with type 2 diabetes mellitus (T2DM) compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Patients who were newly initiated on GLP1-RA were propensity score matched to patients who were newly initiated on DPP4i. We evaluated the primary outcome, composite VTE, identified using ICD-10 (International Classification of Diseases, Tenth Revision) codes, within 12 months of the initiation of GLP1-RA or DPP4i. The study cohort comprised 540 258 patients with 270 129 individuals receiving either GLP1-RA or DPP4i. Over 12 months of follow-up, patients who received GLP1-RA had a lower incidence of VTE compared with patients who received DPP4i (6.1 vs 7.6 events per 1000 patient-years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.73-0.83). This was similar for pulmonary embolism (2.9 vs 3.8 events per 1000 patient-years; HR, 0.74; 95% CI, 0.68-0.82) and deep vein thrombosis (3.9 vs 4.7 events per 1000 patient-years; HR, 0.81; 95% CI, 0.75-0.88). In this propensity score-matched, TTE study, patients with T2DM who received a GLP1-RA had a lower risk of VTE at 1 year compared with patients who received DPP4i.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chiang CH, Song J, Chang YC, et al. Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation. Blood Adv. 2025. PMID: 39908569. doi:10.1182/bloodadvances.2025015871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。